IL309166A - Pasidine mimesis for the treatment of hereditary hemochromatosis - Google Patents
Pasidine mimesis for the treatment of hereditary hemochromatosisInfo
- Publication number
- IL309166A IL309166A IL309166A IL30916623A IL309166A IL 309166 A IL309166 A IL 309166A IL 309166 A IL309166 A IL 309166A IL 30916623 A IL30916623 A IL 30916623A IL 309166 A IL309166 A IL 309166A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- compound
- peptide
- isovaleric acid
- palm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163210453P | 2021-06-14 | 2021-06-14 | |
| US202163252001P | 2021-10-04 | 2021-10-04 | |
| US202263349841P | 2022-06-07 | 2022-06-07 | |
| PCT/US2022/033378 WO2022266060A1 (en) | 2021-06-14 | 2022-06-14 | Hepcidin mimetics for treatment of hereditary hemochromatosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309166A true IL309166A (en) | 2024-02-01 |
Family
ID=84527344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309166A IL309166A (en) | 2021-06-14 | 2022-06-14 | Pasidine mimesis for the treatment of hereditary hemochromatosis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240293511A1 (https=) |
| EP (2) | EP4355763A4 (https=) |
| JP (1) | JP2024520861A (https=) |
| KR (1) | KR20240021833A (https=) |
| AU (1) | AU2022293672A1 (https=) |
| BR (1) | BR112023026381A2 (https=) |
| CA (1) | CA3220871A1 (https=) |
| IL (1) | IL309166A (https=) |
| MX (1) | MX2023015021A (https=) |
| TW (1) | TW202317604A (https=) |
| WO (1) | WO2022266060A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| HRP20211448T1 (hr) | 2014-05-16 | 2021-12-24 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrin tioeter peptidni antagonisti |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA3167751A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7397239B2 (ja) | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ．ベー． | インターロイキン－２３受容体のペプチド阻害剤の組成物 |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| WO2025207760A1 (en) * | 2024-03-27 | 2025-10-02 | Protagonist Therapeutics, Inc. | Formulations of a hepcidin peptide analogue |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) * | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| WO2015200916A2 (en) * | 2014-06-27 | 2015-12-30 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
| EP3240799B1 (en) * | 2014-12-29 | 2021-03-31 | The Regents of the University of California | S-alkylated hepcidin peptides and methods of making and using thereof |
| US20190002503A1 (en) * | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| PH12022550510A1 (en) * | 2019-09-03 | 2023-09-04 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
-
2022
- 2022-06-14 IL IL309166A patent/IL309166A/en unknown
- 2022-06-14 EP EP22825644.2A patent/EP4355763A4/en active Pending
- 2022-06-14 JP JP2023577141A patent/JP2024520861A/ja active Pending
- 2022-06-14 KR KR1020237044819A patent/KR20240021833A/ko active Pending
- 2022-06-14 CA CA3220871A patent/CA3220871A1/en active Pending
- 2022-06-14 AU AU2022293672A patent/AU2022293672A1/en active Pending
- 2022-06-14 BR BR112023026381A patent/BR112023026381A2/pt unknown
- 2022-06-14 TW TW111122040A patent/TW202317604A/zh unknown
- 2022-06-14 US US18/570,004 patent/US20240293511A1/en active Pending
- 2022-06-14 WO PCT/US2022/033378 patent/WO2022266060A1/en not_active Ceased
- 2022-06-14 EP EP26151778.3A patent/EP4737477A2/en active Pending
- 2022-06-14 MX MX2023015021A patent/MX2023015021A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024520861A (ja) | 2024-05-24 |
| EP4737477A2 (en) | 2026-05-06 |
| US20240293511A1 (en) | 2024-09-05 |
| EP4355763A1 (en) | 2024-04-24 |
| KR20240021833A (ko) | 2024-02-19 |
| AU2022293672A9 (en) | 2024-01-11 |
| AU2022293672A1 (en) | 2023-12-14 |
| TW202317604A (zh) | 2023-05-01 |
| BR112023026381A2 (pt) | 2024-03-05 |
| WO2022266060A1 (en) | 2022-12-22 |
| CA3220871A1 (en) | 2022-12-22 |
| EP4355763A4 (en) | 2025-07-30 |
| MX2023015021A (es) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4737477A2 (en) | Hepcidin mimetics for treatment of hereditary hemochromatosis | |
| US12269856B2 (en) | Hepcidin analogues and uses thereof | |
| EP4025592B1 (en) | Conjugated hepcidin mimetics for use in treating of polycythemia vera | |
| EP4501952A2 (en) | Conjugated hepcidin mimetics | |
| JP2026048851A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| US20250360187A1 (en) | Hepcidin mimetics for treatment of sickle cell disease | |
| WO2022212698A1 (en) | Conjugated hepcidin mimetics | |
| WO2018128828A1 (en) | Novel hepcidin mimetics and uses thereof | |
| WO2024011188A1 (en) | Combination therapy for treatment of iron overload diseases | |
| JP2949129B2 (ja) | 胃腸運動刺激活性を有するモチリン類似ポリペプチド | |
| EP3433259B1 (en) | Conjugates of tacrolimus, their compositions, and their uses | |
| JP7440132B2 (ja) | 二重特異性融合ポリペプチド化合物 | |
| CN117480176A (zh) | 用于治疗遗传性血色病的铁调素模拟物 | |
| HK40084564A (en) | Hepcidin analogues and uses thereof | |
| HK40072695B (zh) | 双特异性融合多肽化合物 | |
| HK40072695A (zh) | 双特异性融合多肽化合物 | |
| HK1220112B (en) | Hepcidin analogues and uses therof | |
| NZ751741B2 (en) | Hepcidin analogues and uses therof |